

Stephen P Mcadoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562170/publications.pdf>

Version: 2024-02-01

121
papers

3,418
citations

159585

30
h-index

175258

52
g-index

135
all docs

135
docs citations

135
times ranked

5425
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet, The</i> , 2021, 397, 1178-1181. | 13.7 | 279 |
| 2 | Anti-Glomerular Basement Membrane Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1162-1172. | 4.5 | 259 |
| 3 | Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329. | 0.9 | 188 |
| 4 | BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. <i>Nature Communications</i> , 2017, 8, 16040. | 12.8 | 156 |
| 5 | Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. <i>Kidney International</i> , 2017, 92, 693-702. | 5.2 | 154 |
| 6 | High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1969-1975. | 6.1 | 128 |
| 7 | Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 63-73. | 0.7 | 96 |
| 8 | COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1145-1146. | 6.1 | 85 |
| 9 | 2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618. | 5.8 | 79 |
| 10 | Acute Iron Deprivation Reprograms Human Macrophage Metabolism and Reduces Inflammation In Vivo. <i>Cell Reports</i> , 2019, 28, 498-511.e5. | 6.4 | 75 |
| 11 | Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93. | 30.5 | 74 |
| 12 | Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. <i>Lancet, The</i> , 2021, 398, 1038-1041. | 13.7 | 73 |
| 13 | Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 63-72. | 4.5 | 72 |
| 14 | Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. <i>Journal of Immunology</i> , 2012, 189, 3751-3758. | 0.8 | 65 |
| 15 | Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. <i>Rheumatology</i> , 2018, 57, 1156-1161. | 1.9 | 58 |
| 16 | Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, . | 6.0 | 58 |
| 17 | Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477. | 5.2 | 58 |
| 18 | Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. <i>Lancet, The</i> , 2021, 398, 1482-1484. | 13.7 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100137. | 6.5 | 56 |
| 20 | Anti-glomerular basement membrane disease during the COVID-19 pandemic. <i>Kidney International</i> , 2020, 98, 780-781. | 5.2 | 56 |
| 21 | Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2099-2107. | 0.7 | 55 |
| 22 | Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 1262-1268. | 5.2 | 53 |
| 23 | Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2291-2302. | 6.1 | 46 |
| 24 | Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32. | 1.9 | 42 |
| 25 | A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 260-268. | 1.9 | 40 |
| 26 | Fostamatinib disodium. <i>Drugs of the Future</i> , 2011, 36, 273. | 0.1 | 40 |
| 27 | Anti-Glomerular Basement Membrane Disease. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 651-673. | 1.9 | 35 |
| 28 | Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719. | 5.6 | 35 |
| 29 | Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. <i>Lancet</i> , The, 2022, 399, 800-802. | 13.7 | 35 |
| 30 | Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. <i>Kidney International</i> , 2015, 88, 52-60. | 5.2 | 34 |
| 31 | Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. <i>Rheumatology</i> , 2016, 55, 1437-1442. | 1.9 | 34 |
| 32 | Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2753-2756. | 6.1 | 34 |
| 33 | Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. <i>Kidney International</i> , 2020, 97, 1196-1207. | 5.2 | 34 |
| 34 | Primary IgA nephropathy: current challenges and future prospects. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 137-148. | 1.8 | 32 |
| 35 | Measuring the quality of end of life management in patients with advanced kidney disease: results from the pan-Thames renal audit group. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1548-1554. | 0.7 | 31 |
| 36 | Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. <i>Kidney International Reports</i> , 2021, 6, 46-55. | 0.8 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2021, 100, 1316-1324. | 5.2 | 26 |
| 38 | Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1406-1409. | 0.8 | 26 |
| 39 | Proteinase-3 Antineutrophil Cytoplasm Antibody Positivity in Patients Without Primary Systemic Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 336-340. | 0.9 | 24 |
| 40 | Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. <i>Nephron</i> , 2016, 133, 261-269. | 1.8 | 24 |
| 41 | Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838. | 6.1 | 23 |
| 42 | Renal tubular disease in the era of combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 1831-1836. | 2.2 | 22 |
| 43 | Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 889-896. | 2.9 | 22 |
| 44 | Antiglomerular Basement Membrane Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 494-503. | 2.1 | 21 |
| 45 | Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410. | 0.7 | 21 |
| 46 | Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661. | 1.9 | 20 |
| 47 | Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 496-503. | 1.6 | 19 |
| 48 | Collagen IV α 3 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture $\text{\textcircled{TM}}$ s and Alport diseases. <i>Journal of Biological Chemistry</i> , 2021, 296, 100590. | 3.4 | 19 |
| 49 | ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2567-2582. | 3.5 | 19 |
| 50 | New Therapeutic Targets in Antineutrophil Cytoplasm Antibody $\text{\textcircled{TM}}$ -Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 361-370. | 5.6 | 18 |
| 51 | Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i129-i138. | 0.7 | 17 |
| 52 | Is there a role for TNF α blockade in ANCA-associated vasculitis and glomerulonephritis?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i80-i88. | 0.7 | 17 |
| 53 | Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. <i>Transplantation</i> , 2021, 105, 151-157. | 1.0 | 17 |
| 54 | Membranous Glomerulonephritis With $\text{\textcircled{TM}}$ Crescents. <i>Kidney International Reports</i> , 2019, 4, 1577-1584. | 0.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Live Imaging of Monocyte Subsets in Immune Complex-Mediated Glomerulonephritis Reveals Distinct Phenotypes and Effector Functions. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2523-2542. | 6.1 | 16 |
| 56 | Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1324-1326. | 4.5 | 13 |
| 57 | Experimental crescentic glomerulonephritis: a new bicongenic rat model. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1477-86. | 2.4 | 12 |
| 58 | Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. <i>Rheumatology</i> , 2015, 54, 1025-1032. | 1.9 | 12 |
| 59 | Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 208-210. | 2.9 | 10 |
| 60 | IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 763-769. | 0.5 | 9 |
| 61 | COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1091-1092. | 5.6 | 9 |
| 62 | Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. <i>Kidney International</i> , 2021, 99, 488-489. | 5.2 | 8 |
| 63 | Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. <i>Arthritis Research and Therapy</i> , 2021, 23, 77. | 3.5 | 8 |
| 64 | Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease. <i>Frontiers in Immunology</i> , 2021, 12, 671052. | 4.8 | 8 |
| 65 | ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907. | 0.8 | 8 |
| 66 | Long-term effects of Covid-19 on the kidney. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 621-622. | 0.5 | 8 |
| 67 | Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. <i>Rheumatology</i> , 2021, , . | 1.9 | 7 |
| 68 | Should Rituximab Be Used to Prevent Relapse in Patients with ANCA-Associated Vasculitis?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 641-644. | 4.5 | 6 |
| 69 | Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 739-742. | 0.7 | 6 |
| 70 | SYK inhibition in experimental autoimmune vasculitis and its glomerular expression in ANCA-associated vasculitis. <i>Lancet, The</i> , 2014, 383, S72. | 13.7 | 5 |
| 71 | Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731. | 1.9 | 5 |
| 72 | SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. <i>Kidney Medicine</i> , 2021, 3, 54-59.e1. | 2.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. <i>Scientific Reports</i> , 2022, 12, 3330. | 3.3 | 5 |
| 74 | Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 313-324. | 1.4 | 4 |
| 75 | Characterisation of an enhanced preclinical model of experimental MPO-ANCA autoimmune vasculitis. <i>Journal of Pathology</i> , 2021, 255, 107-119. | 4.5 | 4 |
| 76 | A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury During the COVID-19 Pandemic. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 4 |
| 77 | COVID-19 vaccination in patients with immunity-mediated kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 790-791. | 9.6 | 4 |
| 78 | L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture's disease). <i>Presse Medicale</i> , 2013, 42, 625-628. | 1.9 | 3 |
| 79 | Oral potassium binders: increasing flexibility in times of crisis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1446-1448. | 0.7 | 3 |
| 80 | Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 1402-1406. | 0.8 | 3 |
| 81 | Glomerulonephritis and autoimmune vasculitis are independent of $P2RX7$ but may depend on alternative inflammasome pathways. <i>Journal of Pathology</i> , 2022, 257, 300-313. | 4.5 | 3 |
| 82 | Peroxidasin- α a Novel Autoantigen in Anti-GBM Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2605.2-2607. | 6.1 | 2 |
| 83 | Secondary glomerular disease. <i>Medicine</i> , 2019, 47, 644-648. | 0.4 | 2 |
| 84 | Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis: reply. <i>Rheumatology</i> , 2019, 58, 1119-1119. | 1.9 | 2 |
| 85 | Multimodal Imaging of Granulomatosis With Polyangiitis Aortitis Complicated by Severe Aortic Regurgitation and Complete Heart Block. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009879. | 2.6 | 2 |
| 86 | Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE. <i>Nature Reviews Nephrology</i> , 2021, 17, 439-440. | 9.6 | 2 |
| 87 | Anti-glomerular Basement Membrane Disease. , 2014, , 50-56. | | 2 |
| 88 | The authors reply:. <i>Kidney International</i> , 2022, 101, 648-649. | 5.2 | 2 |
| 89 | Acute renal failure in diabetes: looking beyond diabetic retinopathy. <i>Clinical Medicine</i> , 2011, 11, 629-629. | 1.9 | 1 |
| 90 | Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine. <i>Presse Medicale</i> , 2013, 42, 753. | 1.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339. | 0.8 | 1 |
| 92 | 212. FOSTAMATINIB TREATMENT OF A NEW MODEL OF MPO-ANCA VASCULITIS IN WKY RATS INDUCED BY ADMINISTRATION OF A SUBNEPHRITIC DOSE OF NEPHROTOXIC SERUM AFTER IMMUNIZATION WITH HUMAN MYELOPEROXIDASE. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 1 |
| 93 | 213. LEUCOCYTE SPLEEN TYROSINE KINASE IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 1 |
| 94 | Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2968.2-2968. | 6.1 | 1 |
| 95 | Maintenance rituximab treatment for ANCA-associated vasculitis: to be continued?. <i>Rheumatology</i> , 2021, 60, 1010-1012. | 1.9 | 1 |
| 96 | Masked crystalline light chain tubulopathy and podocytopathy with focal segmental glomerulosclerosis: a rare MGRS-associated renal lesion. <i>Histopathology</i> , 2021, 79, 265-268. | 2.9 | 1 |
| 97 | Diffuse crescentic glomerulonephritis presenting with preserved renal function. <i>Rheumatology</i> , 2021, 60, iii18-iii20. | 1.9 | 1 |
| 98 | The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2022, 101, 201-204. | 5.2 | 1 |
| 99 | Immunodeficiency-associated renal Burkitt lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 769-769. | 2.5 | 0 |
| 100 | FP159 PLASMAPHERESIS, RITUXIMAB AND LOW-DOSE CYCLOPHOSPHAMIDE FOR REMISSION INDUCTION THERAPY IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i82-i83. | 0.7 | 0 |
| 101 | FP198 SPLEEN TYROSINE KINASE EXPRESSION IN HUMAN NEUTROPHILS IN AAV. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i96-i97. | 0.7 | 0 |
| 102 | 306. PLASMAPHERESIS, RITUXIMAB AND LOW-DOSE CYCLOPHOSPHAMIDE FOR REMISSION INDUCTION THERAPY IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 103 | 270. COMPARATIVE ANALYSIS OF COCAINE-ASSOCIATED LIMITED AUTOIMMUNE DISEASE WITH A PRIMARY LOCALIZED GPA COHORT. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 104 | 210. THE CALPROTECTIN/RAGE/ TLR4 AXIS IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 105 | 211. A NOVEL P2X7 KNOCKOUT RAT IS NOT PROTECTED FROM EXPERIMENTAL GLOMERULONEPHRITIS OR VASCULITIS. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 106 | 214. THE EFFECT OF P2X7 ANTAGONISM ON NEPHROTOXIC NEPHRITIS. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 107 | 220. DEFINING THE PATHOGENESIS OF ANCA AND ANTI-GBM DOUBLE POSITIVITY. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |
| 108 | 260. LONG TERM OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS PRESENTING WITH SEVERE RENAL DYSFUNCTION. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | 321.â€fLONG-TERM FOLLOW UP OF A GLUCOCORTICOID-MINIMIZING REGIMEN FOR REMISSION-INDUCTION IN ANCA- ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, . | 1.9 | 0 |
| 110 | 121.â€fMEST-C SCORE IN ADULT HENOCH-SCHÃ–NLEIN PURPURA NEPHRITIS. Rheumatology, 2019, 58, . | 1.9 | 0 |
| 111 | P97â€€...Rituximab treatment for eosinophilic granulomatosis with polyangiitis. , 2019, , . | | 0 |
| 112 | P0374TREATMENT EFFICACY OF BIOSIMILAR RITUXIMAB (TRUXIMA) COMPARED TO THE ORIGINATOR (MABTHERA) IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2020, 35, . | 0.7 | 0 |
| 113 | MO004THE SAFETY PROFILE OF REPEAT RITUXIMAB TREATMENT IN ANCA-ASSOCIATED VASCULITIS - A 10 YEAR SINGLE CENTRE STUDY. Nephrology Dialysis Transplantation, 2020, 35, . | 0.7 | 0 |
| 114 | P0357VALIDATION OF THE ANCA RENAL RISK SCORE IN A LONDON COHORT: POTENTIAL IMPACT OF TREATMENT ON PREDICTION OUTCOME. Nephrology Dialysis Transplantation, 2020, 35, . | 0.7 | 0 |
| 115 | P0383A LONG-TERM RETROSPECTIVE OUTCOME ANALYSIS OF ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, . | 0.7 | 0 |
| 116 | Resolving thromboinflammation. Blood, 2021, 137, 1444-1446. | 1.4 | 0 |
| 117 | MO245OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY*. Nephrology Dialysis Transplantation, 2021, 36, . | 0.7 | 0 |
| 118 | New Treatment Options for Pituitary Granulomatosis With Polyangiitis. Journal of the Endocrine Society, 2021, 5, A594-A594. | 0.2 | 0 |
| 119 | Rapidly Progressive Glomerulonephritis. , 0, , . | | 0 |
| 120 | AB0511â€€...INTERNATIONAL CONSENSUS ON ANCA TESTING AND INTERPRETATION BEYOND SYSTEMIC VASCULITIS. Annals of the Rheumatic Diseases, 2020, 79, 1553.2-1553. | 0.9 | 0 |
| 121 | ANCA-Associated Vasculitis, Anti-GBM Disease, Lupus Nephritis. Nephrology Self-assessment Program: NephSAP, 2020, 19, 88-98. | 3.0 | 0 |